Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017)

Cannabis Investment Report – Overview of FDA‑Approved Cannabinoid Pharmaceuticals (Dec 2017) The passage is a routine industry summary of approved cannabinoid drugs and their regulatory status. It contains no specific allegations, names of officials, financial transactions, or controversial actions that would merit investigative follow‑up. Consequently it offers negligible investigative value. Key insights: Lists FDA‑approved cannabinoid medicines: Marinol, Syndros, Cesamet, Sativex.; Notes schedule classifications under the U.S. Controlled Substances Act.; Mentions GW Pharmaceuticals as manufacturer of Sativex.